Streetwise
Lauren Rudd
Sunday, January 27, 2013
You Cannot Predict the Future
If you are going to invest on Wall Street, please be
cognizant of the fact that there is no relationship between historical and
future stock prices. The past will not predict the future unless you have the
exact same initial conditions, which is impossible.
Does that mean you ignore historical data? No, you simply
need to put the data in proper perspective. It is possible to ascertain, with a
degree of assuredness, certain price pattern characteristics from which you can
deduce with a degree of confidence the likelihood of a price movement in a
specific direction.
Wait a second; didn’t you just say that the past cannot
predict the future and that there is no relationship between historical and
future stock prices? Yes, but you are not predicting the future. What you are
doing is analyzing the one thing that investment prices have in common...that
they are a reflection of the hopes, fears, optimism and greed of the market’s
participants. In other words, the sum total of those emotions is what directs
the price level of an investment.
As Garfield Drew noted in his book, “New Methods for Profit
in the Stock Market,” the quoted price of a stock is never what the stock is
worth but rather what people think it is worth.
Martin Pring wrote in his book, “Technical Analysis
Explained,” the price of a share of stock is a reflection of the changes in
investor attitude, while time measures recurrence of those changes and volume is
essentially a measure of the intensity of those changes.
Because the price patterns of stock prices have been
repeatedly analyzed and catalogued, technical analysis distills down to a
self-fulfilling prophecy. If everyone believes a pattern means an investment
vehicle’s price will rise, the upshot is an upward price move.
Therefore, your objective, via technical analysis, is to
analyze the mood of the crowd and then take either a similar or a contrarian
position. Unfortunately, whenever the price of a security draws an inordinate
amount of attention there is also a tendency to lean on boisterous
prognosticators for advice. That is a mistake. Never take the opinions you hear
or read (including mine) to be the gospel.
Continuing with that line of reasoning, no matter how
“in-favor” or “out-of-favor” a particular investment is never let anyone
pressure you into a knee-jerk reaction. A person selling an investment is
unequivocally biased. It does not matter how many letters they have after their
name, how sincere they appear, or how long you have known them; they sell for a
living. Always obtain an independent second opinion, either from your own
research or from an unbiased professional.
Virtually everyone can learn to undertake at least a minimal
analysis. Consider, for example, MWI Veterinary Supply, (MWIV). The Company is a
leading distributor of animal health products both here and in the United
Kingdom.
MWI sells both companion animal and production animal
products, which include pharmaceuticals, vaccines, parasiticides, diagnostics,
micro feed ingredients, supplies, pet food, capital equipment and nutritional
products. MWI also is a leading innovator and provider of value-added services
and technologies used by veterinarians and producers.
For its fiscal year ended September 30, revenues increased
32.6 percent, while earnings rose 25.6 percent to $4.23 per share. MWI's gross
profit increased by 29.8 percent, representing 12.9 percent of revenues, while
operating income increased 24.9 percent. Sales, general and administrative
expenses were 8.3 percent of revenue.
The company’s share price rose 67 percent during 2012. For
its guidance going forward, the company is estimating a 10.1 percent growth in
revenue and earnings of between $4.66 and $4.80 per share.
The intrinsic value using the discounted earnings model is $122 per share, while
the more conservative free cash flow to the firm model yields an intrinsic value
of $154 per share. The shares recently closed at $114.56. My earnings estimate
for 2013 is $4.75 per share with a 12-month price target on the shares of $128
for a capital gain of 12.3 percent.